Dr. Edwin P. Alyea

Dr. Edwin P. Alyea spesialiserer seg på behandling av blodkreftpasienter som vurderer stamcelle- eller benmargstransplantasjoner. I løpet av de siste 20 årene har det vært betydelige fremskritt innen transplantasjon, noe som har resultert i bedre resultater. Disse fremskrittene inkluderer kapasiteten til å bruke lavere kjemoterapidoser for å redusere toksisitet hos pasienter, samt metoder for å redusere sannsynligheten for tilbakefall. Jeg er interessert i å bruke nye medisiner og teknikker for å forbedre resultatene etter stamcelletransplantasjon for maligne blodsykdommer. Det er avgjørende å samarbeide med pasienter for å definere deres behandlingsmål og det beste handlingsforløpet. I mange år etter transplantasjonen deres har jeg elsket å jobbe med pasienter og deres familier.

Styresertifisering

American Board of Internal Med, Medical Oncology

Fellesskap

Medisinsk onkologi, Dana-Farber Cancer Institute (Massachusetts), 1992-1995

Residency

Internmedisin, Brigham and Women's Hospital (Massachusetts), 1989-1992

Kunnskap

MD, Duke University, 1989

• Voksen benmarg og stamcelletransplantasjon
• Autolog transplantasjon
• Allogen transplantasjon
• Syngenisk transplantasjon

• Hourigan, Christopher S., Laura W. Dillon, Gege Gui, Brent R. Logan, Mingwei Fei, Jack Ghannam, Yuesheng Li, et al. “Impact of Conditioning Intensity of Allogeneic Transplantation for Akutt myeloid leukemi With Genomic Evidence of Residual Disease.” J Clin Oncol 38, nei. 12 (20. april 2020): 1273–83. https://doi.org/10.1200/JCO.19.03011.
• Soiffer, Robert J., Haesook T. Kim, Joseph McGuirk, Mitchell E. Horwitz, Laura Johnston, Mrinal M. Patnaik, Witold Rybka, et al. “Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.” J Clin Oncol 35, nei. 36 (20. desember 2017): 4003–11. https://doi.org/10.1200/JCO.2017.75.8177.
• Liu, Hien Duong, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani, Taiga Nishihori, Baldeep Wirk, Amer Beitinjaneh, et al. “Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.” Biol blodmargstransplantasjon 23, nei. 5 (mai 2017): 767–75. https://doi.org/10.1016/j.bbmt.2017.01.078.
• Scott, Bart L., Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine, David L. Porter, Richard T. Maziarz, et al. “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.” J Clin Oncol 35, nei. 11 (10. april 2017): 1154–61. https://doi.org/10.1200/JCO.2016.70.7091.
• Shaffer, Brian C., Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Michael R. Grunwald, et al. “Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.” J Clin Oncol 34, nei. 16 (1. juni 2016): 1864–71. https://doi.org/10.1200/JCO.2015.65.0515.
• Devine, Steven M., Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, et al. “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.” J Clin Oncol 33, nei. 35 (10. desember 2015): 4167–75. https://doi.org/10.1200/JCO.2015.62.7273.
• Jacobson, Caron A., Lixian Sun, Haesook T. Kim, Sean M. McDonough, Carol G. Reynolds, Michael Schowalter, John Koreth, et al. “Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.” Biol blodmargstransplantasjon 20, nei. 5 (mai 2014): 668–75. https://doi.org/10.1016/j.bbmt.2014.01.021.
• Cutler, Corey, Haesook T. Kim, Bhavjot Bindra, Stefanie Sarantopoulos, Vincent T. Ho, Yi-Bin Chen, Jacalyn Rosenblatt, et al. “Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.” Blood 122, nr. 8 (22. august 2013): 1510–17. https://doi.org/10.1182/blood-2013-04-495895.
• Porcheray, Fabrice, David B. Miklos, Blair H. Floyd, Stefanie Sarantopoulos, Roberto Bellucci, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea, Jerome Ritz, and Emmanuel Zorn. “Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation.” transplantasjon 92, nei. 3 (15. august 2011): 359–65. https://doi.org/10.1097/TP.0b013e3182244cc3.